A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Duke Medical Center, Duke University, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Duke Cancer Institute, Yale University, Smilow Cancer Hospital, Azienda Ospedaliera San Camillo-Forlanini, Hôpital Européen Georges-Pompidou, Institute of Cancer Research, Tulane University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2590534607
